TY  - JOUR
AU  - Blanco-Lobo, Pilar 
AU  - Guisado-Hernandez, Paloma
AU  - Villaoslada, Isabel
AU  - de-Felipe, Beatriz
AU  - Carreras, Carmen
AU  - Rodriguez, Hector
AU  - Carazo-Gallego, Begoña
AU  - Mendez-Echevarria, Ana
AU  - Lucena, Jose Manuel
AU  - Ortiz-Aljaro, Pilar 
AU  - Castro, Maria Jose
AU  - Noguera-Ucles, Jose Francisco
AU  - Milner, Joshua D
AU  - McCann, Katelyn
AU  - Zimmerman, Ofer
AU  - Freeman, Alexandra F
AU  - Lionakis, Michail S
AU  - Holland, Steven M
AU  - Neth, Olaf
AU  - Olbrich, Peter
PY  - 2022
DO  - 10.1007/s10875-022-01273-x
UR  - http://hdl.handle.net/10668/20631
T2  - Journal of clinical immunology
AB  - STAT1 gain-of-function (GOF) and dominant-negative (DN) STAT3 syndromes share clinical manifestations including infectious and inflammatory manifestations. Targeted treatment with Janus-kinase (JAK) inhibitors shows promising results in treating STAT1...
LA  - en
PB  - Springer
KW  - DN STAT3
KW  - JAK-STAT pathway
KW  - STAT1 GOF
KW  - Ruxolitinib
KW  - Chemokines
KW  - Cytokines
KW  - Humans
KW  - Interferons
KW  - Interleukin-6
KW  - Janus Kinase Inhibitors
KW  - Mutation
KW  - Nitriles
KW  - Phosphorylation
KW  - Pyrazoles
KW  - Pyrimidines
KW  - STAT1 Transcription Factor
KW  - STAT3 Transcription Factor
TI  - Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
TY  - research article
VL  - 42
ER  -